Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
about
Endoscopic scoring indices for evaluation of disease activity in Crohn’s diseaseTreating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseasesSafety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study.Assessment of histologic disease activity in Crohn's disease: a systematic review.Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in ChinaHigh Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.Review article: the histological assessment of disease activity in ulcerative colitis.Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease.Histologic scoring indices for evaluation of disease activity in Crohn's disease.Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications.Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy.High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease.Anti-TNFα therapy in IBD alters brain activity reflecting visceral sensory function and cognitive-affective biases.Use of color Doppler ultrasonography for evaluating vascularity of small intestinal lesions in Crohn's disease: correlation with endoscopic and surgical macroscopic findings.Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity
P2860
Q26470550-1B582C31-27B2-4FBD-B745-25BD4D557D64Q27008246-5245B661-455E-4A36-A757-3EA70F41F92FQ34429618-0C3FEC80-3ACD-4B17-BCBB-40E6A862AD34Q35228055-8E84FC49-EEA0-4AED-BBD7-DE39373FCB96Q36193147-3EA554B4-2C28-4553-B6AD-8C5A6765339AQ36347059-DC5D989B-67A7-4613-937F-4CD28522C8E3Q37427620-F1972DEC-ACF2-4AA7-B512-2777347DD6B6Q37601498-FB957C8F-1388-4FB7-86C2-D2D57550D347Q38365049-7AB3706A-7882-4949-B524-A7D83378A35CQ38573248-46B31291-1A17-4E5B-B4EB-20F4AEC4D2D4Q38647797-257EDF35-E647-40B4-B039-8813924BF139Q38668188-670E0244-E1FE-45F1-BBFB-33ECCDA0E62CQ38677581-76D6C3A9-087E-4F2B-BEB3-44A63C4C6092Q38797791-17F376E1-C74F-43D2-91C1-C698C272E263Q38950036-AA301CDB-AE05-453D-949F-ECBAEA6CB464Q40038096-106EF287-A65F-4B1E-91E5-37D7672F3511Q40926333-3A2FDF1A-4505-4E9B-9195-315B40BD3D98Q41329796-C66D864B-1418-4E55-BF6C-6FF27FEEF88EQ41807969-FE2BBFF4-B8D9-48DB-BC3C-48EB93749080Q47282148-0CE4308B-0C98-4A19-BCFD-56CEC43D2F28Q47743116-B4C394F4-BBA8-4278-BDD6-55CB602B0A24Q50986872-C4E6FBDE-C8E2-4513-91A2-FCA3ED699848Q52666803-C0AA346E-4541-46BC-B09B-0E463BA9EB90Q54429680-3310D506-E010-4F98-AD5B-D6CBC573603DQ55191136-4826655F-09A4-4A46-BEF3-2C08E976BF1BQ58806562-6D295FB0-3B0F-41AF-9137-4C32FF963A83
P2860
Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Achievement of deep remission ...... h TNFα-blocking agents in IBD.
@en
Achievement of deep remission ...... h TNFα-blocking agents in IBD.
@nl
type
label
Achievement of deep remission ...... h TNFα-blocking agents in IBD.
@en
Achievement of deep remission ...... h TNFα-blocking agents in IBD.
@nl
prefLabel
Achievement of deep remission ...... h TNFα-blocking agents in IBD.
@en
Achievement of deep remission ...... h TNFα-blocking agents in IBD.
@nl
P2093
P2860
P1476
Achievement of deep remission ...... h TNFα-blocking agents in IBD.
@en
P2093
Airi Jussila
Helena Kemppainen
Henna Rautiainen
Juha Kuisma
Kaija-Leena Kolho
Markku Nissinen
Pauliina Molander
Ritva Koskela
Taina Sipponen
Timo Blomster
P2860
P304
P356
10.1016/J.CROHNS.2012.10.018
P577
2012-11-21T00:00:00Z